Shareholders who lost money in shares of Inspire Medical Systems, Inc. (NYSE: INSP) Should Contact Wolf Haldenstein Immediately

Lead Plaintiff Deadline is January 5, 2026

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors in Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”) securities that a securities class action has been filed on behalf of all investors who purchased shares between August 6, 2024 and August 4, 2025 (the “Class Period”). Investors have until January 5, 2026 to seek appointment as lead plaintiff.

PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

Allegations

The complaint filed alleges Inspire Medical Systems, Inc., and certain company officers or directors engaged in securities fraud or other unlawful business practices. The lawsuit centers on whether the company misled investors about the launch and performance of its new Inspire V sleep apnea device.

Background and Disclosure

On August 4, 2025, Inspire disclosed several setbacks affecting the rollout of Inspire V:

1. Training and Onboarding Delays:
   Many centers failed to complete necessary training, contracting, and onboarding steps before purchasing or implanting the device.
2. Billing and Medicare Reimbursement Issues:
   Although Inspire V’s CPT code was approved for Medicare, billing software updates did not take effect until July 1, delaying claims and reimbursement processing.
   → Many centers continued using the older Inspire IV device.
3. Excess Inventory Problems:
   Surplus inventory further hampered the Inspire V rollout.
   
   

Because of these issues, Inspire slashed its earnings guidance by more than 80% — from $2.20–$2.30 per share down to $0.40–$0.50 per share.

Reaction

On this news, the price of Inspire’s common stock declined more than 32%, from a close of $129.95 per share on August 4, 2025, to close at $87.91 per share on August 5, 2025 wiping out $1.2 billion in market capitalization in a single day of trading. From the Company's Class Period stock price closing high of $216.71 per share on September 23, 2024, Inspire Medical's stock price dropped an astonishing $127.00 per share, or nearly 60%, erasing billions of dollars from the Company's market capitalization.

Lead Plaintiff Deadline

Investors who suffered losses have until January 5, 2026, to seek appointment as lead plaintiff.

Why Wolf Haldenstein Adler Freeman & Herz LLP?:

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: classmember@whafh.com
• Contact Person: Gregory Stone, Director of Case and Financial Analysis
  
  

Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.